NVAX - Novavax, Inc.
| Previous Close | 1.72 |
| Open | 1.72 |
| Bid | 1.72 x 800 |
| Ask | 1.75 x 35000 |
| Day's Range | 1.71 - 1.75 |
| 52 Week Range | 0.73 - 2.75 |
| Volume | 4,930,750 |
| Avg. Volume | 9,597,880 |
| Market Cap | 651.753M |
| Beta | 2.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.63 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- InvestorPlace•3 days ago
3 Biotech Stocks That Will Thrive Amid Market Instability
The U.S. stock market is facing a severe volatility since the last couple of months despite a strong start this year. This downside can mainly be attributable to a potentially damaging trade war between the world’s two largest economies, United States and China, since this February.Source: Shutterstock
- Motley Fool•5 days ago
Buy Novavax After Its Latest Pullback?
Novavax has a couple of promising experimental vaccines. But could even more dilution be around the corner?
- GlobeNewswire•6 days ago
Novavax Announces Closing of Public Offering
GAITHERSBURG, Md., April 16, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...
- GlobeNewswire•6 days ago
Novavax Announces Closing of Public Offering
GAITHERSBURG, Md., April 16, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced the closing of the underwritten ...
- ACCESSWIRE•9 days ago
Today’s Research Reports on Stocks to Watch: Novavax and Pfizer
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on ...
- Motley Fool•10 days ago
Here's Why Novavax, Inc. Is Sinking
Shares plunged after the clinical-stage vaccine maker gave details on the pricing of its recently announced common stock offering.
- MarketWatch•10 days ago
Novavax's stock plunges on heavy volume after public offering prices at deep discount
Shares of Novavax Inc. tumbled 16% in active premarket trade Thursday, after the biotechnology company said its relatively large public offering of stock priced at a deep discount. Volume topped 8.5 million ...
- GlobeNewswire•11 days ago
Novavax Prices Public Offering of Common Stock
GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced ...
- GlobeNewswire•11 days ago
Novavax Prices Public Offering of Common Stock
GAITHERSBURG, Md., April 11, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten ...
- American City Business Journals•11 days ago
Novavax announces plans for public offering
Details of the offering — including how many shares the company would sell, at what price, and when — are still being hammered out.
- GlobeNewswire•11 days ago
Novavax Announces Proposed Public Offering of Common Stock
GAITHERSBURG, Md., April 11, 2018-- Novavax, Inc., a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it intends to offer ...
- Zacks•16 days ago
Pick 3 Biotech Money-Spinning Bets Amid Market Instability
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.
- Investopedia•17 days ago
Top 3 Healthcare Penny Stocks for 2018
These three healthcare penny stocks are poised for positive performance in 2018.
- Motley Fool•19 days ago
3 Top Small-Cap Biotech Stocks for Aggressive Investors
These small biotechs could be huge winners. But they also have huge risks.
- GlobeNewswire•20 days ago
Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress
Update on RSV F Vaccine Phase 3 Prepare (TM) trial for infants via maternal immunization Results from Phase 1/2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose ...
- GlobeNewswire•20 days ago
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
Update on RSV F Vaccine Phase 3 Prepare™ trial for infants via maternal immunization Results from Phase 1/ 2 trial of NanoFlu vaccine demonstrating improved immune responses compared to egg-based, high-dose ...
- Market Realist•24 days ago
Analysts’ Ratings for Sorrento and Its Peers in March 2018
Sorrento Therapeutics (SRNE) is a clinical-stage biotechnology company. Its research programs are targeted at autoimmune, inflammatory, and neurodegenerative diseases and pain indications. Essentially, Sorrento Therapeutics is an antibody-centric company and leverages its G-MAB library to generate product candidates.
Market Realist•24 days agoWhat Analysts Recommend for AbbVie and Peers in March 2018
AbbVie (ABBV) is a global biopharmaceutical company with a focus on research. AbbVie’s pipeline also includes medicines for cystic fibrosis and women’s health. Of the 23 analysts covering AbbVie in March 2018, four analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating.
- Market Realist•24 days ago
Analysts’ Ratings for Omeros and Peers in March 2018
An Investor's Overview of OmerosCompany overview
- Motley Fool•25 days ago
Forget Merck: Novavax, Inc. Is a Better Vaccine Stock
Novavax better than Merck? For some investors, the answer could be "yes."
- Market Realist•27 days ago
Exploring Xencor’s Cash Flows
In 2017, Xencor generated $31.9 million from investing activities compared to its expenditure of $213.6 million in 2016. The company’s investing activities mainly consist of the purchase and sale of marketable securities and the acquisition of intellectual property and equipment. In 2017, Xencor used $39.2 million in marketable securities.
Market Realist•27 days agoAnalysts’ Recommendations for Xencor and Its Peers in March
Xencor’s proprietary technology platform, XmAb, enables it to create antibody product candidates for the treatment of autoimmune and allergic diseases. Of the six analysts covering Xencor in March 2018, three have given the stock “strong buy” ratings, and two have given it “buy” ratings, while one analyst has given it a “hold” rating. The mean rating for the stock is 1.67, and its target price is $36.67.
- Simply Wall St.•last month
When Will Novavax Inc (NASDAQ:NVAX) Become Profitable?
Novavax Inc’s (NASDAQ:NVAX): Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The US$685.25MRead More...
